422 related articles for article (PubMed ID: 25915038)
1. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.
Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M
BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783
[TBL] [Abstract][Full Text] [Related]
3. 1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M.
Kundu A; Khouri MG; Aryana S; Firestone GL
Carcinogenesis; 2017 Dec; 38(12):1207-1217. PubMed ID: 29028954
[TBL] [Abstract][Full Text] [Related]
4. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
[TBL] [Abstract][Full Text] [Related]
5. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML
Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo anti-tumor activity of CoQ0 against melanoma cells: inhibition of metastasis and induction of cell-cycle arrest and apoptosis through modulation of Wnt/β-catenin signaling pathways.
Hseu YC; Thiyagarajan V; Tsou HT; Lin KY; Chen HJ; Lin CM; Liao JW; Yang HL
Oncotarget; 2016 Apr; 7(16):22409-26. PubMed ID: 26968952
[TBL] [Abstract][Full Text] [Related]
7. [Nuclear beta-catenin localization is not sufficient for canonical Wnt signaling activation in human meianoma cell lines].
Kulikova KV; Posviatenko AV; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
Mol Biol (Mosk); 2011; 45(5):884-91. PubMed ID: 22393786
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
Gray JE; Infante JR; Brail LH; Simon GR; Cooksey JF; Jones SF; Farrington DL; Yeo A; Jackson KA; Chow KH; Zamek-Gliszczynski MJ; Burris HA
Invest New Drugs; 2015 Dec; 33(6):1187-96. PubMed ID: 26403509
[TBL] [Abstract][Full Text] [Related]
9. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
11. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
[TBL] [Abstract][Full Text] [Related]
12. Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk.
Zamek-Gliszczynski MJ; Mohutsky MA; Rehmel JL; Ke AB
Drug Metab Dispos; 2014 Jun; 42(6):1008-15. PubMed ID: 24658455
[TBL] [Abstract][Full Text] [Related]
13. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
14. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
15. Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators.
Mazur M; Bujak A; Matloka M; Janowska S; Gunerka P; Bojarski L; Stanczak A; Klejman A; Bednarek A; Lamparska-Przybysz M; Wieczorek M
Anal Biochem; 2015 Apr; 475():56-67. PubMed ID: 25659657
[TBL] [Abstract][Full Text] [Related]
16. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling.
Liu Y; Liu YZ; Zhang RX; Wang X; Meng ZJ; Huang J; Wu K; Luo JY; Zuo GW; Chen L; Yin LJ; Deng ZL; He BC
Int J Oncol; 2014 Aug; 45(2):795-803. PubMed ID: 24859848
[TBL] [Abstract][Full Text] [Related]
17. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
[TBL] [Abstract][Full Text] [Related]
18. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Capasso A; Bagby SM; Dailey KL; Currimjee N; Yacob BW; Ionkina A; Frank JG; Kim DJ; George C; Lee YB; Benaim E; Gittleman B; Hartman SJ; Tan AC; Kim J; Pitts TM; Eckhardt SG; Tentler JJ; Diamond JR
Mol Cancer Ther; 2019 Nov; 18(11):1916-1925. PubMed ID: 31488700
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
Yeh CT; Rao YK; Ye M; Wu WS; Chang TC; Wang LS; Wu CH; Wu AT; Tzeng YM
Toxicol Appl Pharmacol; 2012 May; 261(1):31-41. PubMed ID: 22465936
[TBL] [Abstract][Full Text] [Related]
20. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
Etnyre D; Stone AL; Fong JT; Jacobs RJ; Uppada SB; Botting GM; Rajanna S; Moravec DN; Shambannagari MR; Crees Z; Girard J; Bertram C; Puri N
Cancer Biol Ther; 2014 Sep; 15(9):1129-41. PubMed ID: 24914950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]